Icosagen
developed anti-human BNDF antibody clone 3C11 played
prominent role in Neuroscience and JBC
publications.

In March, 2016 two research groups published their results in
Neuroscience and JBC using Icosagen-developed
anti-human BDNF antibody.

Anti-BDNF
clone 3C11 made it possible for Chacón-Fernández et al. to discover that human and rat megakaryocytes express the BDNF. At the
same time, Zunino and colleagues determined that the levels of mature BDNF
protein were lower in the neocortex of En2-/- mice, as compared to WT,
indicating pathogenic role of altered BDNF signalling in this mouse model of
autism spectrum disorders.

“The lack of suitable, i.e. sensitive and specific reagents allowing the
reliable detection of BDNF after Western blotting has been a real problem in
the field. This has now been resolved following the development by Icosagen
(Tartu, Estonia) of a remarkably useful mouse monoclonal antibody
designated 3C11. It recognises mammalian BDNF and pro-BDNF on Western
blot with high selectivity and sensitivity. For illustration, see:
Brain-derived Neurotrophic Factor in Megakaryocytes. Chacón-Fernández P,
Säuberli K, Colzani M, Moreau T, Ghevaert C, Barde YA. J Biol Chem. 2016 Mar
22. pii: jbc.M116.720029.”